Roivant Sciences

Affimed Reports 2023 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 28, 2024
Research, EGFR, GVHD, NSCLC, Genentech, ASH, AML, PD, Disease, International, International Financial Reporting Standards, Patient, Webcast, EFS, EDT, CRS, Cancer, Record, Insurance, Trial of the century, Bank statement, Investment, Safety, Workforce, Roivant Sciences, PFS, IASB, Hodgkin lymphoma, Book, NK, HL, Cytokine release syndrome

MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.

Key Points: 
  • MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the year ended December 31, 2023.
  • Based on the promising results, Affimed expanded enrollment in this cohort to 40 patients.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on March 28, 2024, at 8:30 a.m. EDT / 13:30 CET to discuss full year 2023 financial results and corporate developments.

Coda Octopus Group Reports Fiscal First Quarter 2024 Financial Results

Retrieved on: 
Monday, March 18, 2024
Research, Tax, Development, Transport, NIWC, Intelligence, Business, Marine, Oceanography, Sale, News, Person, Engineering, Rail transport by country, Human voice, CODA, Business plan, Diving, Traction, United States Navy, Safety, Calendar, Navy, Roivant Sciences

ORLANDO, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in 3D/4D/5D/6D imaging sonar technology for real time subsea intelligence and cutting-edge diving technology, today reported its unaudited financial results for its fiscal first quarter ended January 31, 2024 (FQ2024).

Key Points: 
  • ORLANDO, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in 3D/4D/5D/6D imaging sonar technology for real time subsea intelligence and cutting-edge diving technology, today reported its unaudited financial results for its fiscal first quarter ended January 31, 2024 (FQ2024).
  • Annmarie Gayle, CODA’s Chairman and CEO, commented: “Our First Quarter 2024 results were in alignment with our internal Business Plan but down compared to our First Quarter 2023.
  • “
    The Company’s full financial results, including its Quarterly Report for the First Quarter of 2024, are available at www.nasdaq.com/symbol/coda/sec-filings .
  • CODA will host a conference call today, March 18, 2024, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) to discuss its results for the First Quarter ended January 31, 2024.

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
LNP, HBV, Court, PD, Research, Virology, Expert witness, CFBV, AASLD, Construction, Nivolumab, Investment, Arbutus, HBsAg, EASL, Vaccine, Interim, Safety, COVID-19, Pharmacokinetics, Roivant Sciences, Patient, Clinical trial, Congress, RNA interference, DNA, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus is advancing AB-101 into part two of this clinical trial which involves dosing healthy subjects with multiple-ascending doses of AB-101.
  • Roivant Sciences Ltd. owned approximately 23% of the Company’s outstanding common shares as of December 31, 2023.

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Retrieved on: 
Tuesday, February 6, 2024
CFO, Certified Public Accountant, Biotechnology, PPD, Roivant Sciences, University, Management

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO).

Key Points: 
  • NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO).
  • Anne succeeds Stephen Bardin as the Company’s CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition.
  • “Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence,” said atai Co-founder and Chief Executive Officer, Florian Brand.
  • “I am honored to take on the leadership of atai’s world-class finance team and look forward to continuing to build a strong financial foundation to advance our R&D programs,” said Anne Johnson.

Sigyn Therapeutics Releases Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Fresenius Medical Care, FDA, Hope, Health, Cancer, Inflammation, Patent, Lipopolysaccharide, Kidney disease, Horizon, Annual report, Death, University, IDE, Letter, Merck, Dialysis, Sepsis, Life, Antibody, Mortality, Therapy, Risk, Toxicity, Patient, Acquisition, AB toxin, ESRD, Hospital, Infection, SAN, DaVita Inc., Community-acquired pneumonia, Horizon Therapeutics, Roivant Sciences, Cardiovascular disease, Security (finance), Pharmaceutical industry

SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.

Key Points: 
  • SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce.
  • The goal of this letter is to help you better understand our opportunities, our challenges, and decision-making processes.
  • In that submission, our endeavors were solely predicated on the development and clinical advancement of Sigyn TherapyTM.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties.

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Kite Pharma, Engineering management, Tufts University, Marketing, Lilly, Migraine, Johnson & Johnson, Amgen, Sale, AstraZeneca, Daiichi Sankyo, Eli Lilly, Jan Vansina, Business administration, Engineering, WebMD, MBA, Chemical engineering, Doctor of Philosophy, Roivant Sciences, Therapy, Eli Lilly and Company, Consumer service, University, Washington State University, Worcester Polytechnic Institute, Iowa State University, SVP, Corporation, Pharmaceutical industry

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

Key Points: 
  • ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
  • “We are delighted to welcome Christi Shaw, Mert Aktar and David Marek, and the tremendous expertise and wise counsel they represent, to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta's Board of Directors.
  • Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines.
  • Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience bridging science and business in pharmaceuticals and biotechnology.

Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions

Retrieved on: 
Wednesday, December 6, 2023
Workforce, Gene editing, TTK, Amgen, Breast cancer, Royal college, TCR, FDA, Acquisition, Cell, Research, Internal medicine, Drug, Physician, SAN, Panitumumab, Therapy, Oncology, Cancer, University, HPK1, Queen's University, Roivant Sciences, Patient, Surgeon, AML, PLK4, Pharmaceutical industry

TORONTO and SAN FRANCISCO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel first-in-class medicines for unmet needs in cancer, today announced that it is realigning its pipeline, workforce and management structure to support its highest value program and extend its cash runway to prioritize the execution of key near term value drivers and clinical milestones.

Key Points: 
  • Dr. Sidhu brings to Treadwell an extensive track record of success over the last nearly 20 years in hematologic and solid tumor oncology research and development.
  • “Roger brings a unique and broad set of skills and strategic thinking to Treadwell over a long and successful career.
  • We are confident that under his leadership, Treadwell will aggressively advance into an exciting new chapter in our mission to address unmet needs in difficult to treat cancers with first-in-class medicines,” said Shane Burgess, Executive Chair of Treadwell Therapeutics.
  • We would like to extend our deep gratitude to the Treadwell team, investigators and patients involved in our clinical programs.

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Record, Safety, Annual general meeting, Cytokine release syndrome, Research, Type, Silicon Valley Bank, ASH, Non-Hodgkin lymphoma, CRS, International, Bank statement, Book, Silicon, Insurance, Patient, Genentech, FDA, Hodgkin lymphoma, Lung cancer, International Financial Reporting Standards, GVHD, Monroe Dunaway Anderson, International Accounting Standards Board, IASB, Cholangiocarcinoma, ORR, Roivant Sciences, Cancer, Trial of the century, Financial toxicity, Haematopoietic system, HL, EST, AML, Society, NHL, PTCL, NK, NSCLC, Cryptocurrency, Medical device, Vaccine, Pharmaceutical industry, Rare-earth element, Audit, Euro, Affimer

MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

Key Points: 
  • MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.
  • Total revenue for the quarter ended September 30, 2023, was €2.0 million compared with €14.9 million for the quarter ended September 30, 2022.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on November 14, 2023, at 8:30 a.m. EST / 14:30 CET to discuss third quarter 2023 financial results and corporate developments.

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

Retrieved on: 
Friday, November 10, 2023
Literature, Patient, MIT, Human, Harvard Medical School, FDA, Biology, Roivant Sciences

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately.
  • Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total.
  • Dr. Sukhatme also informs Roivant’s view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio.
  • Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer.

NCCN Announces Funding for Advanced Prostate Cancer Research Projects

Retrieved on: 
Tuesday, November 21, 2023
Relugolix, Research, Gonadotropin-releasing hormone, NCCN, ORP, National Comprehensive Cancer Network, Database, Patient, Knowledge, Collaboration, MD, Cancer, Roivant Sciences, ADT, Oncology, Registry, Medical imaging

PLYMOUTH MEETING, Pa., Nov. 21, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative investigator-initiated research involving the medication relugolix. Funding will be provided through support from Pfizer Global Medical Grants and Sumitomo Pharma America, Inc. (previously known as Myovant Sciences, Inc.).

Key Points: 
  • The National Comprehensive Cancer Network's Oncology Research Program selects projects to advance scientific knowledge of combination therapies that include relugolix in the treatment of patients with advanced prostate cancer.
  • PLYMOUTH MEETING, Pa., Nov. 21, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® ( NCCN ®) Oncology Research Program ( ORP ) today announced grants awarded for developing innovative investigator-initiated research involving the medication relugolix.
  • Their research will help us learn more about how to care for people with advanced prostate cancer."
  • The NCCN ORP fosters innovation and knowledge discovery that improve the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions.